Literature DB >> 17095247

Thioredoxin in cancer--role of histone deacetylase inhibitors.

Paul A Marks1.   

Abstract

Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17095247      PMCID： PMC2766865          DOI： 10.1016/j.semcancer.2006.09.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  93 in total

1.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Authors:  Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.

Authors:  Seung Jin Kim; Yasuo Miyoshi; Tetsuya Taguchi; Yasuhiro Tamaki; Hajime Nakamura; Junji Yodoi; Kikuya Kato; Shinzaburo Noguchi
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

Review 4.  Histone deacetylase inhibitors: discovery and development as anticancer agents.

Authors:  Paul A Marks; Milos Dokmanovic
Journal:  Expert Opin Investig Drugs       Date:  2005-12       Impact factor: 6.206

5.  Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells.

Authors:  Ruth E Freeman; Jiri Neuzil
Journal:  FEBS Lett       Date:  2006-04-21       Impact factor: 4.124

Review 6.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

7.  Asymmetric inheritance of oxidatively damaged proteins during cytokinesis.

Authors:  Hugo Aguilaniu; Lena Gustafsson; Michel Rigoulet; Thomas Nyström
Journal:  Science       Date:  2003-02-27       Impact factor: 47.728

8.  Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK.

Authors:  Timothy A McKinsey; Koichiro Kuwahara; Svetlana Bezprozvannaya; Eric N Olson
Journal:  Mol Biol Cell       Date:  2005-10-19       Impact factor: 4.138

9.  Histone acetylation-mediated regulation of genes in leukaemic cells.

Authors:  A E Chambers; S Banerjee; T Chaplin; J Dunne; S Debernardi; S P Joel; B D Young
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

Review 10.  Thioredoxin redox control of cell growth and death and the effects of inhibitors.

Authors:  G Powis; D L Kirkpatrick; M Angulo; A Baker
Journal:  Chem Biol Interact       Date:  1998-04-24       Impact factor: 5.192
View more
  22 in total

1.  A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Authors:  Naris Nilubol; Roxanne Merkel; Lily Yang; Dhaval Patel; James C Reynolds; Samira M Sadowski; Vladimir Neychev; Electron Kebebew
Journal:  Clin Endocrinol (Oxf)       Date:  2016-09-08       Impact factor: 3.478

Review 2.  The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Authors:  Paul A Marks
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

3.  Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.

Authors:  Suhyuk Lee; Jaehyuk Jang; Hyungtaek Jeon; Jisu Lee; Seung-Min Yoo; Jinsung Park; Myung-Shin Lee
Journal:  J Microbiol       Date:  2016-10-29       Impact factor: 3.422

Review 4.  Targeting Histone Deacetylases in Diseases: Where Are We?

Authors:  Rosaria Benedetti; Mariarosaria Conte; Lucia Altucci
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

5.  Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.

Authors:  Meng Lou; Qian Liu; Guoping Ren; Jiling Zeng; Xueping Xiang; Yongfeng Ding; Qinghui Lin; Tingting Zhong; Xia Liu; Lijun Zhu; Hongyan Qi; Jing Shen; Haoran Li; Jimin Shao
Journal:  J Biol Chem       Date:  2017-04-14       Impact factor: 5.157

Review 6.  Histone deacetylase inhibitors: emerging mechanisms of resistance.

Authors:  Robert W Robey; Arup R Chakraborty; Agnes Basseville; Victoria Luchenko; Julian Bahr; Zhirong Zhan; Susan E Bates
Journal:  Mol Pharm       Date:  2011-10-07       Impact factor: 4.939

7.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

8.  Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1.

Authors:  Seungjeong Song; Sang Won Kang; Chulhee Choi
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

Review 9.  Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor.

Authors:  Susannah K Leaver; Niall S MacCallum; Vasisht Pingle; Matthew B Hacking; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

Review 10.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.